Esperoct? (turoctocog alfa pegol, N8-GP) approved in the EU ... Read more


Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at c ... Read more


Novo Nordisk A/S - Share repurchase programme ... Read more


Novo Nordisk A/S - Share repurchase programme ... Read more


Novo Nordisk A/S – Share repurchase programme ... Read more


Esperoct? (turoctocog alfa pegol, N8-GP) approved in the EU ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
Press material is intended for media.


Novo Nordisk Media

production Denmark

News from Biopharm on ISTH

8 July -?On ISTH in Australia two press releases were presented: Concizumab phase 2 data demonstrate its potential as a safe and efficacious subcutaneous prophylaxis treatment for all patients with haemophilia. “These results are particularly important for patients with haemophilia B and inhibitors, for whom treatment options are limited, as underscored by the FDA having granted concizumab Breakthrough Therapy Designation for the treatment of haemophilia B with inhibitors,” said Amy Shapiro, investigator in the explorer4 trial and lead author of the paper in Blood.

Refixia?: New data show nonacog beta pegol (N9-GP) is effective and well tolerated for the prevention and treatment of bleeding in children with haemophilia B.?“Minimising and managing bleeds in children with haemophilia B can be especially challenging for families,” said Ludovic Helfgott, executive vice president of Novo Nordisk Biopharm Operations. “We are delighted that these results further support the good efficacy of nonacog beta pegol in preventing and treating bleeds in children with haemophilia B.”

Download the?full press release on concizumab?and the press release on Refixia?


Esperoct? (turoctocog alfa pegol, N8-GP) approved in the EU

20 June -?The European Commission has granted marketing authorisation for Esperoct? for the treatment of adolescents (≥12 years of age) and adults with haemophilia A. The authorisation covers all 28 European Union member states.?“We are excited about the approval of Esperoct? in the EU, and we consider it an important expansion of the treatment options for patients with haemophilia A,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are confident that Esperoct? will provide people with haemophilia A a simple and less burdensome, predictable dosing regimen for prophylaxis as well as treatment of bleeding episodes, resulting in improved quality of life."

Download the full announcement


Circular for zero

Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact??

30 April?-?Novo Nordisk today announced that it will achieve its target to use only renewable electricity in its global production facilities by 2020. The announcement follows a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk’s entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity.

Read more about?Circular for Zero?and download the full press release?


Towards a cure

When Becky Furuta was told her cycling career was over due to her diabetes, she defied doctors' orders to rise to the top of her profession.

Read the story about Becky,?pro-cyclist at Team Novo Nordisk,?or listen to her story in the podcast

Subscribe to our perspectives?


Red Cross and Novo Nordisk in ground-breaking partnership to tackle chronic care in humanitarian crises

The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally;?support for ICRC’s and DRC’s health programmes;?2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.

Read CEO Lars Fruergaard's reflections and more about the partnership



Financial results for second quarter of 2019

When Paris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years.?

Watch the documentary, 'Safely in the Rainbow', on YouTube

Financial results 2019

9 August - first half?

1 November - third quarter?


Novo Nordisk in brief

Defeat NCDs

Zeana Massoud Said has type 1 diabetes. Zeana lives in Tanzania

The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.

Read more details in the press release

电竞菠菜DJBET <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>